Cipla shares rose 4% after Citi placed the stock on a 90-day Positive Catalyst Watch with a 'Buy' rating. The brokerage expects growth from potential US approvals for gFlovent and gVentolin, a US business rebound, and strong domestic respiratory portfolio performance.
Tap to vote and see what everyone thinks.
Summary by ByteBrief